Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern.
about
Detection and analysis of resistance mutations of hepatitis B virusAssociation of preexisting drug-resistance mutations and treatment failure in hepatitis B patientsHepatitis B virus (HBV) subgenotypes C2 and B2 differ in lamivudine- and adefovir-resistance-associated mutational patterns in HBV-infected Chinese patients.Long-term outcomes and dynamics of mutants associated with lamivudine-adefovir rescue therapy in patients with lamivudine-resistant chronic hepatitis B.Antiviral therapies: focus on hepatitis B reverse transcriptaseAntiviral efficacies of currently available rescue therapies for multidrug-resistant chronic hepatitis B.De novo entecavir+adefovir dipivoxil+lamivudine triple-resistance mutations resulting from sequential therapy with adefovir dipivoxil, and lamivudine.Compensatory variances of drug-induced hepatitis B virus YMDD mutations.Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patientsIs there any value to hepatitis B virus genotype analysis?New paradigms in hepatitis B management: only diamonds are forever.Hepatitis B virus genotypes: epidemiological and clinical relevance in Asia.Long-term real-world entecavir therapy in treatment-naïve hepatitis B patients: base-line hepatitis B virus DNA and hepatitis B surface antigen levels predict virologic response.Comparison of the efficacies of entecavir 0.5 and 1.0 mg combined with adefovir in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analogue treatments.Management of chronic hepatitis B patients: efficacy & limitation of nucleos(t)ide analogues.JSH Guidelines for the Management of Hepatitis B Virus Infection.Telbivudine protects renal function in patients with chronic hepatitis B infection in conjunction with adefovir-based combination therapy.A complete genomic analysis of hepatitis B virus isolated from 516 Chinese patients with different clinical manifestations.Long-term efficacy and emergence of multidrug resistance in patients with lamivudine-refractory chronic hepatitis B treated by combination therapy with adefovir plus lamivudine.The efficacy of adefovir plus entecavir combination therapy in patients with chronic hepatitis B refractory to both lamivudine and adefovir.Prevention and management of drug resistant hepatitis B virus infections.Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B.
P2860
Q28266666-C0CED4A4-7245-4B6E-AD11-1760DA87268DQ28535003-B3810E80-DD32-4697-AD61-C10FC8247D38Q34433062-96C81BCC-C5C1-4BE3-ADE8-4076CA932161Q34809263-61C3C772-3126-471C-AD59-9E0E20390E35Q36467514-F3F4B41D-CEBD-4E9E-A2B5-CAEE963B2DB1Q36756364-4DBF3574-53A1-4904-A1FD-E84673A86D39Q36800501-3D07FE4E-F746-47CF-9302-52BDFD74CE5BQ37181728-A25B0989-7835-4B43-BD03-6763BC0FF8EAQ37229870-91D9D4C7-8C7A-4801-9762-1B5910E81F9BQ37959290-DF895512-2E4E-4C5D-9322-F9AE52F5B9B8Q38588187-023EBD7C-9F0E-483C-9F7C-D6CEAE49ABA2Q38805019-38A311FC-E295-4B39-9FDA-4C58B5E49394Q40493686-DF1283D5-2C90-4020-8320-64568334ED6FQ41466695-D44AB0ED-071D-4106-8AD7-436A13B3CAEFQ41910180-7692E7C1-EE19-46DC-936A-31A83A434EA1Q42244740-23E3CD97-43E6-4B7A-8B87-2F992DAC42C8Q42248312-81D6EBEC-A6A4-46A6-BCC3-3363E98DB932Q42255173-FFDB129C-E3CF-4EE7-A61B-D73943863ECCQ42278002-BB429218-CBBF-40D7-9522-3C62F0D369F7Q43824738-DE9AFDCA-D5A3-4F3D-84FC-D8F40A325AACQ45356906-5D340E56-A833-461D-B56F-AC9420F9066CQ51873464-6694CEA7-9590-4CEA-880E-61D63145FAB6
P2860
Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Four-year study of lamivudine ...... d resistance mutation pattern.
@en
Four-year study of lamivudine ...... d resistance mutation pattern.
@nl
type
label
Four-year study of lamivudine ...... d resistance mutation pattern.
@en
Four-year study of lamivudine ...... d resistance mutation pattern.
@nl
prefLabel
Four-year study of lamivudine ...... d resistance mutation pattern.
@en
Four-year study of lamivudine ...... d resistance mutation pattern.
@nl
P2093
P2860
P1476
Four-year study of lamivudine ...... d resistance mutation pattern.
@en
P2093
H Niitsuma
K Fukushima
T Shimosegawa
P2860
P304
P356
10.1111/J.1365-2893.2010.01301.X
P577
2011-03-01T00:00:00Z